A clinical study to assess the effect of vildagliptin on beta cell function in drug naive patients with type 2 diabetes.
Phase of Trial: Phase III
Latest Information Update: 03 Jan 2013
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Novartis
- 06 May 2011 Results published in the Diabetologia.
- 28 Feb 2011 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 25 Jun 2010 Primary endpoint 'C peptide levels' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History